BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SenzaGen - ECPv6.7.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://senzagen.com
X-WR-CALDESC:Events for SenzaGen
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20260422T160000
DTEND;TZID=Europe/Stockholm:20260422T170000
DTSTAMP:20260429T184405
CREATED:20260327T081555Z
LAST-MODIFIED:20260401T071711Z
UID:36730-1776873600-1776877200@senzagen.com
SUMMARY:Webinar: Advancing NAMs for respiratory sensitization testing
DESCRIPTION:Scientific highlights from 2026 SOT\nJoin us for an insightful webinar exploring the latest advancements in respiratory sensitization testing\, an emerging field facing challenges in both scientific and regulatory landscapes. We will highlight how New Approach Methodologies (NAMs) are advancing human-relevant\, non-animal strategies for respiratory hazard assessment. \nTogether with guest speakers Dr. Emily Reinke (GDIT) and Dr. Joshua Vaughan (Merck)\, we will discuss key challenges\, outline currently available approaches\, and present new GARD®air data from scientific collaborations\, including results from a recently completed large-scale study (n=100) led by NICEATM\, as well as industry case studies on microbial-based pesticides and proteins. \nIf you missed SenzaGen’s scientific sessions at this year’s SOT in San Diego\, this is your chance to catch up!  \n \nThe webinar will last around 45 minutes\, followed by a live Q&A. If you cannot attend the live event\, register anyway to receive the on-demand recording. \nKey takeaways\n\nRegulatory insights: An up-to-date perspective on the evolving regulatory landscape for respiratory sensitization assessment. \nGARD® advancements: How genomics and machine-learning technologies enable non-animal respiratory sensitization assessment across diverse substance types. \nCase studies: Scientific collaborations with Merck and Bayer on proteins and microbial-based pesticides\, along with a NICEATM-led study on occupational health-related chemicals.\n\nSpeakers\n \nEmily Reinke\, PhD\, DABT\nPrincipal Toxicologist\, Federal Health Division | GDIT (contractor supporting NICEATM) \n\nExpert in NAMs for skin and respiratory sensitization and acute systemic toxicity.\nContributor to U.S. EPA\, JaCVAM\, OECD\, and independent peer review panels.\nFormer Department of Defense representative to ICCVAM (including four years as co-chair).\n\n  \n \nJoshua Vaughan\, PhD\, DABT\nPrincipal Scientist\, Occupational Toxicology and Product Stewardship\, Merck \n\nExpert in occupational and environmental health within pharmaceutical R&D.\nMember of the National Academies Committee on Toxicology.\nExtensive industry experience in toxicology across pharmaceuticals\, biocides/pesticides\, and product safety.\n\n  \n \nAndy Forreryd\, PhD\nScientific Liaison Manager\, SenzaGen \n\nMember of OECD expert group on respiratory sensitization.\nMember of the ISO/TC 194/WG 8 on irritation and sensitization.\nCo-developer of the GARD®skin assay (OECD TG 442E).\n\n  \n \n 
URL:https://senzagen.com/event/webinar-respiratory-sensitization-testing/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/01/Lime-UNIVERSAL-webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260322
DTEND;VALUE=DATE:20260326
DTSTAMP:20260429T184405
CREATED:20260122T141811Z
LAST-MODIFIED:20260312T111337Z
UID:36486-1774137600-1774483199@senzagen.com
SUMMARY:2026 SOT Annual Meeting & ToxExpo
DESCRIPTION:Booth #1934\nSan Diego\, CA\, USA\nJoin our scientific sessions and poster presentations at this year’s SOT\, featuring the latest GARD® data and case studies generated in collaboration with industry leaders. \nMeet us at booth #1934 and discuss your specific testing needs with our scientific team – We help you design testing strategies tailored to your substances and regulatory goals: from “2 out of 3” defined approaches according to OECD 497\, to exploratory studies supporting product development. \n \nExhibitor-Hosted Session\nAdvancing NAMs for Skin and Respiratory Sensitization: UVCBs\, Natural Extracts and Medical Devices \nNew GARD® advances in respiratory sensitization\,  ISO 10993-10 compliance for medical devices\, quantitative potency assessment\, and difficult-to-test samples \nRoom 23A | Tue\, 24 March | 10:45 am-11:45 am\n \n1. Introduction to GARD® technology for skin and respiratory sensitization testing \n🎤Andy Forreryd\, PhD |  Scientific Liaison\, SenzaGen  \n2. Evaluating sensitization potential of medical devices in vitro using GARD®skin assay: a practical in vitro sensitization case study in medical device development \n🎤Yizhong Liu\, PhD\, DABT | Senior Scientist and Toxicologist\, Johnson & Johnson MedTech  \n3. GARD®air for the prediction of respiratory sensitization for substances of regulatory concern \n🎤Emily Reinke\, PhD\, DABT | Principal Toxicologist\, GDIT (contractor supporting NICEATM)  \n4. Respiratory sensitization hazard identification: navigating assay exploration for biocatalytic enzymes \n🎤Joshua Vaughan\, PhD\, DABT | Principal Scientist\, Merck  \nSpeaking in Symposium Sessions\nIn Vitro Testing for Skin Sensitization of Mixtures: Where Science Stands Today \nRoom 7B | Wed\, 25 March | 8:00 am-10:45 am \nChairs: The Honest Company\, Edgewell Personal Care | SenzaGen: Dr Tim Lindberg | SenzaGen: Dr Tim Lindberg \nHuman Health Risk Assessments of Biopesticides: Evaluating Safety for Agricultural Use \nBallroom 6F | Wed\, 25 March | 1:30 PM-4:15 PM \nChairs: Bayer Crop Science\, Corteva Agriscience | SenzaGen: Dr Andy Forreryd \nPosters\n🎫 K764 | #5200 | Case study: Fragrance formulations – Jointly with Coty \nImproving the safety profiles of fragrance formulations: modulating the skin sensitization potential to reduce or eliminate the risk of allergic skin reactions \n🎫 K762 | #5198 | Case study: 2o3 DA applied to UVCBs – Jointly with ExxonMobil \nApplying the “2 out of 3” Defined Approach (OECD 497) to assess skin sensitization potential of UVCBs using the GARD®skin and EpiSensA assays \n🎫 K759 | #5195 | Case study: NESIL prediction for OTC drugs – Jointly with Haleon  \nPredicting NESIL using New Approach Methodologies: a case study on quantitative skin sensitization assessment of topical over-the-counter pharmaceutical candidates \n🎫B175 | #3072 | Medical Device ISO 10993-10 \nIn vitro sensitization assessment of medical device extracts: Prevalidation results of GARD®skin Medical Device for potential inclusion in ISO 10993-10 \n🎫G546 | #3403 | New alternative gene expression platform for GARD® \nRNA-seq can be used for gene expression quantification in the GARD®skin method for assessment of skin sensitizers
URL:https://senzagen.com/event/2026sot/
LOCATION:San Diego\, CA\, United States
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2026/01/2026-SOT-eventpage-banner-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20251202T160000
DTEND;TZID=Europe/Stockholm:20251202T170000
DTSTAMP:20260429T184405
CREATED:20251119T084346Z
LAST-MODIFIED:20251119T163704Z
UID:35877-1764691200-1764694800@senzagen.com
SUMMARY:Webinar: The regulatory shift in biological safety testing
DESCRIPTION:NAMs for skin sensitization ISO 10993-10\nJoin us for an insightful webinar on the evolving role of New Approach Methodologies (NAMs) in biological safety testing of Medical Devices\, with a special focus on skin sensitization – the area currently undergoing the most significant regulatory changes. \nAs ISO standards advance toward reducing animal testing\, understanding these developments is essential for compliance and innovation. We will also touch on related endpoints\, including special irritation\, to provide a more complete perspective on biological safety testing. \nGARDskin: Full pre-validation data \nIn this session\, Dr. Andy Forreryd\, SenzaGen’s expert in in vitro skin sensitization and active member of ISO/TC 194/WG 8\, will share the latest regulatory developments in ISO 10993-10 and present new data from the completed GARD®skin Medical Device pre-validation study—a key milestone toward regulatory acceptance. \nSafe dose levels of potential sensitizers during R&D  \nYou will also gain practical insights from case studies with Sonova and Urgo\, showing how the GARD® technology can efficiently screen novel materials and determine safe levels of potential sensitizers in candidate devices.  \n \nThe webinar will last around 45 minutes\, followed by a live Q&A. If you cannot attend the live event\, register anyway to receive the on-demand recording. \nKey takeaways\n\nRegulatory insights: Stay informed on on the latest developments in ISO 10993-10 and the growing role of in vitro methods. \nGARD® advancements: Learn how GARD® supports both skin sensitization hazard and quantitative potency assessment of Medical Devices\, solid materials and extracts in polar and non-polar vehicles. \nIndustry application: Discover how GARD® is used in regulatory submissions for CE-marking\, early-stage material screening and hypoallergenicity claims.\n\nSpeaker\n \nAndy Forreryd\, PhD\nScientific Liaison Manager @ SenzaGen \n\nCo-developer of the GARD®skin assay (OECD TG 442E).\nMember of the ISO/TC 194/WG 8 on irritation and sensitization.\nMember of OECD expert group on respiratory sensitization.\n\n  \n \n  \n\n 
URL:https://senzagen.com/event/webinar-regulatory-shift-in-biological-safety-testing/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/01/Lime-UNIVERSAL-webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20251119T160000
DTEND;TZID=Europe/Stockholm:20251119T170000
DTSTAMP:20260429T184405
CREATED:20251027T141204Z
LAST-MODIFIED:20251027T151538Z
UID:35671-1763568000-1763571600@senzagen.com
SUMMARY:Webinar: GARDskin in OECD TG 497
DESCRIPTION:Bringing high performance and extended applicability to Defined Approaches for Skin Sensitization (DASS)\nJoin us for a special re-run of our popular webcast to learn more about the inclusion of GARD®skin in OECD TG 497 — what it means and how it can support your regulatory testing strategy. \nDefined Approaches for Skin Sensitization (DASS) is a key regulatory guideline for combining validated in vitro methods to support hazard and potency assessment. The GARDskin assay is now part of two Defined Approaches (DAs): \n\nThe “2 out of 3” DA for hazard identification.\nThe Integrated Testing Strategy (ITS) for hazard identification and potency sub-categorization (1A\, 1B\, NC).\n\nWith demonstrated high performance and broad applicability to hydrophobic substances (Log P > 3.5) and other challenging chemical entities\, GARDskin improves the performance and extends the overall applicability of DASS\, helping to fill data gaps in regulatory skin sensitization testing.   \n \nAgenda\n\nIntroduction to skin sensitization testing and GARD technology.\nGARDskin (OECD TG 442E) and its inclusion in OECD TG 497.\nCase studies: Improving performance and extending the applicability of DASS for challenging samples.\nLive Q&A.\n\nSpeakers \n \nAndy Forreryd\, PhD\nScientific Liaison Manager @ SenzaGen \n\nCo-developer of the GARD®skin assay (OECD TG 442E).\nMember of the ISO/TC 194/WG 8 on irritation and sensitization.\nMember of OECD expert group on respiratory sensitization. \n\n \nHenrik Johansson\, PhD\nChief Scientist @ SenzaGen \n\nCo-developer of the GARD®skin assay (OECD TG 442E).\nMember of the ISO/TC 194/WG 8 for Irritation and Sensitization.\nMember of the OECD Expert Group on Defined Approaches on Skin Sensitization.\n\n  \n \nThe webinar will last around 40 minutes\, followed by a live Q&A. If you cannot attend the live event\, register anyway to receive the on-demand recording. \n\n 
URL:https://senzagen.com/event/webinar-gardskin-in-oecd-497/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/01/Lime-UNIVERSAL-webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251106
DTEND;VALUE=DATE:20251108
DTSTAMP:20260429T184405
CREATED:20250828T142424Z
LAST-MODIFIED:20251028T132753Z
UID:35451-1762387200-1762559999@senzagen.com
SUMMARY:3rd Annual Medical Device Biocompatibility Conference
DESCRIPTION:3rd Annual Medical Device Biocompatibility Conference\n Berlin\, Germany |  Nov 6-7\nCome meet us at this year’s Medical Device Biocompatibility Conference in Berlin\, where SenzaGen’s chief scientist Henrik Johansson will present recent progress in applying New Approach Methodologies (NAMs) for skin sensitization testing within the ISO 10993 framework\, including current regulatory developments and data from GARD®skin for Medical Devices. \nOur group company ToxHub will also present\, sharing insights on regulatory strategies for substance-based medical devices in line with MDR\, while VitroScreen will attend to discuss testing approaches\, including support for mode of action and classification. \nWant to connect with our scientific team while you’re there? \n \nPresentations\n“Building Confidence in New Approach Methodologies (NAMs) for Skin Sensitization Testing of Medical Devices”\n Thursday\, 6th Nov | 13:30 – 14:00 CET\n👤 Speaker: Dr Henrik Johansson\, Chief Scientist at SenzaGen\nKey takeaways:\n\nIntroduction to in vitro biocompatibility testing: Overview of available assays and their regulatory status.\nPre-validation data from GARD®skin for Medical Devices: In vitro skin sensitization testing of Medical Device Extracts for implementation in ISO 10993-10.\nRegulatory Developments in ISO 10993-10: Inclusion of in vitro methods.\nCase study: Integrating in vitro data into CE-marking submissions.\n\n\n“Biocompatibility evaluation of substance-based medical devices”\n Friday\, 7th Nov | 11:40 – 12:10 CET\n👤 Speaker: Dr Carla Landolfi\nKey takeaways:\n\nOverview of biocompatibility evaluation for substance-based medical devices under ISO 10993 and MDR.\nTesting strategies: in vitro\, in vivo\, and non-testing approaches.\nRegulatory challenges and best practices for ensuring patient safety.
URL:https://senzagen.com/event/3rd-annual-medical-device-biocompatibility-conference/
LOCATION:Berlin\, Germany
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/08/MD-Biocompatibility-conference-in-Berlin-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251021
DTEND;VALUE=DATE:20251024
DTSTAMP:20260429T184405
CREATED:20250828T140923Z
LAST-MODIFIED:20250828T193940Z
UID:35446-1761004800-1761263999@senzagen.com
SUMMARY:ASCCT 2025
DESCRIPTION:ASCCT 14th Annual Meeting\n📍 Gaithersburg\, USA | 🗓 October 21–23\, 2025\nMeet us at this year’s ASCCT annual meeting in Gaithersburg\, where SenzaGen’s scientific team will share new insights on quantitative skin sensitization potency assessment and present results from the pre-validation study of GARD®skin Medical Device. \nWhat to connect with us while you are there? \n \nMore information coming soon!
URL:https://senzagen.com/event/ascct-2025/
LOCATION:Gaithersburg\, Md\, USA
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/08/25133-RAD-ASCCT-Annual-Meeting-Graphics_IIVS-Update-1584x396-1-e1756392285881.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251015
DTEND;VALUE=DATE:20251019
DTSTAMP:20260429T184405
CREATED:20250828T135526Z
LAST-MODIFIED:20250828T195046Z
UID:35428-1760486400-1760831999@senzagen.com
SUMMARY:ICT/IUTOX 2025
DESCRIPTION:ICT 2025 / IUTOX 17th International Congress of Toxicology\n📍 Beijing\, China | 🗓 October 15–18\, 2025\nMeet us at this year’s ICT/IUTOX conference in Beijing\, where SenzaGen’s scientific team will share new insights on quantitative skin sensitization potency assessment and present results from the pre-validation study of GARD®skin Medical Device. \nWhat to connect with us while you are there? \n \nPosters\n🎫  #645 | Quantitative skin sensitization potency assessment\nAdvancing in vitro skin sensitization potency assessment using GARDskin Dose-Response \n🎫 #649 | Application for medical devices\nPre-validation results from GARDskin for Medical Devices: In vitro sensitization testing of medical device extracts for implementation in ISO 10993-10
URL:https://senzagen.com/event/ict-iutox-2025/
LOCATION:Beijing\, China
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/08/ICT-banner-e1756389255388.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20251008T160000
DTEND;TZID=Europe/Stockholm:20251008T170000
DTSTAMP:20260429T184405
CREATED:20250822T075505Z
LAST-MODIFIED:20250923T091749Z
UID:35388-1759939200-1759942800@senzagen.com
SUMMARY:Webinar: In vitro skin sensitization potency assessment
DESCRIPTION:Using GARD® to derive PoDs and safe dose levels for skin sensitizers\nChemicals | Natural Extracts | Complex Mixtures \nJoin our upcoming webinar to explore how GARD® enables the derivation of Points of Departure (PoDs) for Quantitative Risk Assessment (QRA) and helps establish safe dose levels for identified sensitizers. \nWith broad applicability to complex mixtures and new raw materials with challenging properties\, GARD® offers a powerful non-animal solution in skin sensitization potency assessment. \nTypical challenges you may face: \n\nYou have a new ingredient that is a sensitizer. At what dose level is it safe to use?\nYou are planning for confirmatory human patch testing (HRIPT). How can you obtain a NESIL value?\nYou are performing a Risk Assessment for a new active ingredient in a complex formulation. How can you get a PoD/NESIL for QRA?\n\nAs practical examples\, we will showcase scientific collaborations with Unilever\, BIC\, Takasago\, dōTERRA\, International Flavors & Fragrances (IFF) and the Research Institute for Fragrance Materials (RIFM). \n \nKey topics\n\nIntroduction to New Approach Methodologies (NAMs) for skin sensitization potency assessment.\nHow to overcome common challenges in deriving PoDs and establishing safe dose levels for skin sensitizers.\nCase studies on Fragrances\, Essential Oils\, Botanical Extracts\, and Complex Mixtures.\n\nThe webinar will last around 30 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording. \nSpeaker\n \nAndy Forreryd\, PhD\nScientific Liaison Manager @ SenzaGen \n\nCo-developer of the GARD®skin assay (OECD TG 442E).\nMember of the ISO/TC 194/WG 8 on irritation and sensitization.\nMember of OECD expert group on respiratory sensitization.
URL:https://senzagen.com/event/webinar-skin-sensitization-potency-assessment/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/01/Lime-UNIVERSAL-webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20251002T140000
DTEND;TZID=Europe/Stockholm:20251002T180000
DTSTAMP:20260429T184405
CREATED:20250828T192933Z
LAST-MODIFIED:20250929T062850Z
UID:35473-1759413600-1759428000@senzagen.com
SUMMARY:Medicon Valley MedTech Network meeting
DESCRIPTION:Understanding Biological Evaluation of Medical Devices\nJoin the next Medicon Valley MedTech Network meeting in Lund to gain insights into the general principles of biological safety evaluation\, what to consider\, why it matters\, and how upcoming changes to ISO 10993-1 may affect the process.  \nSenzaGen’s in vitro skin sensitization expert\, Dr Andy Forreryd\, will be joined by other industry experts to share experiences and discuss the challenges faced in the biological evaluation of medical devices. \nRedefining Biocompatibility Testing: The Role of In Vitro Models in Product Development and regulatory submissions Speaker: Andy Forreryd\, PhD\, Scientific Liaison Manager\, SenzaGen \nRead the full agenda and sign up here \n  \n \n  \n  \n 
URL:https://senzagen.com/event/medicon-valley-medtech-network-meeting/
LOCATION:Lund\, Sweden
CATEGORIES:Seminar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/08/medtech-network-banner-WEB_Final-e1756409677112.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250929T100000
DTEND;TZID=Europe/Stockholm:20250929T190000
DTSTAMP:20260429T184405
CREATED:20250828T131114Z
LAST-MODIFIED:20250828T194205Z
UID:35415-1759140000-1759172400@senzagen.com
SUMMARY:RIFM INFOX 2025
DESCRIPTION:RIFM 2025 Information Exchange (INFOX®) Paris\nFrance Advancing Fragrance Safety Through Innovation\, Science\, and Collaboration\nDate: September 29\, 2025\nLocation: Le Méridien Etoile\, 81 Bd Gouvion-Saint-Cyr\, 75017 Paris\, France\nCome meet SenzaGen’ skin sensitization experts Dr Andy Forreryd and Dr Tim Lindberg at this year’s Research Institute for Fragrance Materials (RIFM) INFOX© meeting in Paris! \nThis exclusive event brings together leading scientists to present the latest advancements in fragrance safety science\, spanning human health and environmental protection. INFOX 2025 is a key forum for shaping the future of safe and sustainable fragrance use\, and we look forward to engaging in the discussions. \nWant to connect with our scientific team while you are in Paris?
URL:https://senzagen.com/event/rifm-infox-2025/
LOCATION:Paris\, France
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/08/INFOX-GENERAL-HEADER-1024x535-1-e1756387095780.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250914
DTEND;VALUE=DATE:20250918
DTSTAMP:20260429T184405
CREATED:20250317T151319Z
LAST-MODIFIED:20250909T111839Z
UID:34391-1757808000-1758153599@senzagen.com
SUMMARY:Eurotox 2025
DESCRIPTION:Eurotox 2025\n Athens\, Greece |  Sep 14-17\nBooth #A24\nAdvancing NAMs for Skin Sensitization Testing\nCome meet us at this year’s Eurotox and take part in our scientific activities\, featuring an industry-hosted session\, poster presentations\, and the latest insights on GARD®. Discover how the method provides high performance\, broad applicability\, and quantitative potency information for skin sensitization testing. \nWant to connect with our scientific team while you’re there? \n \nIndustry-Hosted Session\nRegulatory update: GARD®skin in OECD TG 497\nTime: 12:00-13:00 | Tuesday\, September 16\nVenue: N. Skalkotas Hall\n \nJoin us for an interactive scientific session featuring regulatory updates\, case studies\, and a live Q&A. Key highlights: \n\nRegulatory update: GARD®skin included in OECD TG 497.\nCase studies: UVCBs\, Natural Extracts\, Formulations\, Hydrophobic Substances\, and more.\nScientific collaborations: dōTERRA\, BIC\, and Urgo.\n\nLearn how GARD®skin fits into TG 497 and what this means in practice for your regulatory testing strategy. \nPosters\nSpotlight on Essential oils\, Safe dose levels\, Hypoallergenic claims and more\n🎫 P32-09 #644 | Joint poster with DōTERRA\nComparative analysis of skin sensitization thresholds for essential oils: human\, murine\, and GARDskin Dose-Response \n🎫 P32-12 #731 | Joint poster with BIC Skin Creative\nIn vitro skin sensitization potency assessment using GARDskin Dose-Response: a case study on natural extracts-based skin-binding dyes and dye precursors \n🎫 P32-16 #923 | Joint poster with Urgo\nSupporting industry decision-making and hypoallergenicity claims using an experimental setup combining GARDskin Medical Device and Dose-Response protocols \n🎫 P23-04 #314 | ToxHub poster\nDeriving gender-sensitive Occupational Exposure Limits: Case studies on benperidol and dimethylacetamide \nMore at our booth\nExpert guidance for your regulatory challenges\nMeet ToxHub\, our consultancy unit specializing in toxicological risk assessment and regulatory strategy consulting\, with expertise across medical devices\, pharmaceuticals\, cosmetics and chemicals. \nDiscover how ToxHub can support your needs
URL:https://senzagen.com/event/eurotox-2025/
LOCATION:Athens\, Greece
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/03/2025-eurotox-banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250831
DTEND;VALUE=DATE:20250905
DTSTAMP:20260429T184405
CREATED:20250303T121220Z
LAST-MODIFIED:20250828T194641Z
UID:34240-1756598400-1757030399@senzagen.com
SUMMARY:WC13
DESCRIPTION:13th World Congress on Alternatives and Animal Use in the Life Sciences\n📍 Rio de Janeiro\, Brazil | 🗓 Aug 31-Sep 4\nAt this year’s conference SenzaGen and Unilever co-chair a scientific symposium\, where Dr Andy Forreryd will present how GARD® can be applied to derive a Point-of-Departure (PoD) for quantitative skin sensitization assessment. \n \nSession #79\nUsing NAMs to derive PoDs for NGRA of skin sensitizers: Towards regulatory implementation\nTime: 9:30-11:00 | Tuesday\, September 2\nVenue: Plenary Room\nTogether with speakers from Unilever\, Research Institute for Fragrance Materials (RIFM)\, and Inotiv\, this joint symposium will cover methodological innovations in New Approach Methodologies (NAMs)\, industry case studies on deriving Points of Departure (PoDs) for fragrances\, and the challenges and opportunities for regulatory acceptance. \n \n💻 Incorporating expert knowledge in the Skin Allergy Risk Assessment (SARA) Model: an integrated approach to testing and assessment (IATA) demonstrated in case studies.\nRenato Ivan de Ávila\, PhD @Unilever \n💻 The GARD®skin Dose-Response model to derive a PoD for quantitative skin sensitization assessment.\nAndy Forreryd\, PhD @SenzaGen \n💻 Predicting PoD and potency categories using New Approach Methods: Practical experience from the fragrance industry.\nIsabella Schember\, PhD @Research Institute for Fragrance Materials (RIFM) \n💻 Integrating NAMs for quantitative skin sensitization potency assessment into regulatory frameworks: experience from the work in OECD TG 497\nEmily Reinke\, PhD\, D.A.B.T @Inotiv \nPoster #167\nGARD®skin for Medical Devices: Pre-validation results for implementation in ISO 10993-10\nThe pre-validation study of GARD®skin Medical Device confirms the method is functional\, reproducible and sufficiently accurate to proceed to the validation study phase\, as defined by the ISO TS11796.
URL:https://senzagen.com/event/wc13/
LOCATION:Rio de Janeiro\, Brazil
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/03/WC13-Logo-white-background.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250703T160000
DTEND;TZID=Europe/Stockholm:20250703T170000
DTSTAMP:20260429T184405
CREATED:20250611T091213Z
LAST-MODIFIED:20250630T113645Z
UID:35113-1751558400-1751562000@senzagen.com
SUMMARY:Webcast: GARDskin included in OECD TG 497
DESCRIPTION:Bringing high performance and extended applicability to Defined Approaches for Skin Sensitization (DASS)\nJoin our webcast to learn more about the inclusion of GARD®skin in OECD TG 497— what it means and how it can support your regulatory testing strategy. \nDefined Approaches for Skin Sensitization (DASS) is a key regulatory guideline for combining validated in vitro methods to support hazard and potency assessment. The GARDskin assay is now part of two Defined Approaches (DAs): \n\nThe “2 out of 3” DA for hazard identification.\nThe Integrated Testing Strategy (ITS) for hazard identification and potency sub-categorization (1A\, 1B\, NC).\n\nWith demonstrated high performance and broad applicability to hydrophobic substances (Log P > 3.5) and other challenging chemical entities\, GARDskin improves the performance and extends the overall applicability of DASS\, helping to fill data gaps in regulatory skin sensitization testing.   \n \nAgenda\n\nIntroduction to skin sensitization testing and GARD technology.\nGARDskin (OECD TG 442E) and its inclusion in OECD TG 497.\nCase studies: Improving performance and extending the applicability of DASS for challenging samples.\nLive Q&A.\n\nSpeakers \n \nAndy Forreryd\, PhD\nScientific Liaison Manager @ SenzaGen \n\nCo-developer of the GARD®skin assay (OECD TG 442E).\nMember of the ISO/TC 194/WG 8 on irritation and sensitization.\nMember of OECD expert group on respiratory sensitization. \n\n \nHenrik Johansson\, PhD\nChief Scientist @ SenzaGen \n\nCo-developer of the GARD®skin assay (OECD TG 442E).\nMember of the ISO/TC 194/WG 8 for Irritation and Sensitization.\nMember of the OECD Expert Group on Defined Approaches on Skin Sensitization.\n\n  \n \nThe webinar will last around 40 minutes\, followed by a live Q&A. If you cannot attend the live event\, register anyway to receive the on-demand recording. \n\n 
URL:https://senzagen.com/event/gardskin-in-oecd-497/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2024/11/Bild1-cropped.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250423T160000
DTEND;TZID=Europe/Stockholm:20250423T170000
DTSTAMP:20260429T184405
CREATED:20250312T123507Z
LAST-MODIFIED:20250331T142222Z
UID:34303-1745424000-1745427600@senzagen.com
SUMMARY:Webinar: Scientific highlights from 2025 SOT
DESCRIPTION:Advancing NAMs for Skin Sensitization Testing: Natural Extracts\, Medical Devices and Potency\n\nJoin our upcoming webinar\, where SenzaGen’s expert and guest speakers from dōTERRA and Risk Science Consortium will share insights and case studies on the use of New Approach Methodologies (NAMs) for skin sensitization assessment. \nWe’ll present the latest GARD® data from our research and industry collaborations on Natural Extracts\, UVCBs\, and Essential Oils\, explore new opportunities for potency assessment\, and provide updates on regulatory developments for integrating NAMs into Medical Device testing under ISO 10993-10. \nIf you missed SenzaGen’s poster presentations and scientific session at this year’s SOT in Orlando\, this is your chance to catch up! \nThe webinar will last around 50 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording. \n \nKey takeaways\n\nNew GARD® data on Natural Extracts and Potency Assessment.\nRegulatory update Medical Devices  (ISO 10993-10).\nUser Cases from Clarins\, dōTERRA\, Unilever and more.\n\n\nSpeakers and Agenda\n \nNew GARD® Data on Natural Extracts\, Medical Devices and Skin Sensitization Potency Assessment\nAndy Forreryd\, PhD\nScientific Liaison Manager @ SenzaGen \n\nExpert in in vitro assay development\, genomics\, and machine learning.\nCo-developer of the GARD®skin assay (OECD TG 442E).\nActive member of the ISO/TC 194/WG 8 on irritation and sensitization and OECD expert group on respiratory sensitization.\n\n  \n \nA Comparative Analysis of Human\, Murine\, and GARD®skin Dose-Response Skin Sensitization Thresholds for Essential Oils\nJoe Dawson\nProduct Safety Manager @ dōTERRA International \n\nManages the product safety team at dōTERRA International.\n10 years of experience working as a research scientist in the natural products and cosmetics industries.\nAreas of expertise include literature review\, risk assessment\, and scientific claim substantiation.\n\n \nThey Promised Us Flying Cars: the Use of NAMs for the Safety Assessment of Medical Devices\nRon Brown\nToxicologist @ Risk Science Consortium (Former FDA Scientist) \n\nToxicologist with 35 years of experience in regulatory toxicology and risk assessment.\nFormer FDA reviewer with 25 years of experiences.\nFounding member and former President of the Medical Device and Combination Products Specialty Section of the Society of Toxicology and former President of the Dose-Response Specialty Section of the Society for Risk Analysis.\n\n  \n \n 
URL:https://senzagen.com/event/webinar-2025sot/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/01/Lime-UNIVERSAL-webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250404
DTEND;VALUE=DATE:20250411
DTSTAMP:20260429T184405
CREATED:20250317T145617Z
LAST-MODIFIED:20250317T150648Z
UID:34382-1743724800-1744329599@senzagen.com
SUMMARY:In-cosmetics Global 2025
DESCRIPTION:Meet us at In-cosmetics global in Amsterdam!  \nDate: April 8-10\, 2025
URL:https://senzagen.com/event/2025in-cosmetics-global/
LOCATION:Amsterdam\, Netherlands
CATEGORIES:Conference
ATTACH;FMTTYPE=image/webp:https://senzagen.com/wp-content/uploads/2025/03/INCOS-Global_370x125_Atlas-logo.png.webp
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250404
DTEND;VALUE=DATE:20250405
DTSTAMP:20260429T184405
CREATED:20250317T134428Z
LAST-MODIFIED:20250317T145119Z
UID:34368-1743724800-1743811199@senzagen.com
SUMMARY:2025 SFT annual meeting
DESCRIPTION:Meet us at Swedish Society of Toxicology (SFT)’s annual meeting in Stockholm! This year the theme is “Breaking boundaries: novel methods and approaches advancing toxicology”. \nDate: April 4\, 2025 \nVenue: Samuelssonssalen\, Karolinska Institutet\, Tomtebodavägen 6\, Solna \nSenzaGen’s presentation: Advancing skin sensitization testing with GARD®: Enhancing human relevance and overcoming regulatory challenges \nSpeaker: Tim Lindberg\, PhD\, In vitro Toxicology Expert\, SenzaGen
URL:https://senzagen.com/event/2025sft/
LOCATION:Stockholm\, Sweden
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/03/KI_Samuelssonssalen-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250331
DTEND;VALUE=DATE:20250402
DTSTAMP:20260429T184405
CREATED:20250303T115948Z
LAST-MODIFIED:20250317T085841Z
UID:34234-1743379200-1743551999@senzagen.com
SUMMARY:Forum SOFHYT 2025
DESCRIPTION:Meet us at the SOFHYT (French Society of Occupational Hygienists) forum “From Prevention to Action: The Occupational Hygienist at the Heart of Occupational Health Risk Management” in Paris on March 31 and April 1. \nOral presentation | 1 April
URL:https://senzagen.com/event/sofhyt2025/
LOCATION:Paris\, France
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/03/Forum-SOFHYT.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250326
DTEND;VALUE=DATE:20250328
DTSTAMP:20260429T184405
CREATED:20250303T114445Z
LAST-MODIFIED:20250317T083038Z
UID:34229-1742947200-1743119999@senzagen.com
SUMMARY:6th Annual BTEL Summit & Exhibition
DESCRIPTION:Meet us at the 6th Annual BTEL Summit & Exhibition in Berlin. \nOral presentation | 26 March \nBuilding confidence in New Approach Methodologies (NAMs) for biological safety testing of Medical Devices: a successful case study on skin sensitization testing using GARD®  \nAndy Forreryd\, PhD\nScientific Liaison Manager\, SenzaGen
URL:https://senzagen.com/event/btel2025/
LOCATION:Berlin\, Germany
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/03/2025BTEL-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250316T080000
DTEND;TZID=Europe/Stockholm:20250320T170000
DTSTAMP:20260429T184405
CREATED:20250207T084353Z
LAST-MODIFIED:20250312T122014Z
UID:34052-1742112000-1742490000@senzagen.com
SUMMARY:2025 SOT Annual Meeting & ToxExpo
DESCRIPTION:Booth #637 \nOrange County Convention Center\,  Orlando\, FL. \nMeet us and discover how the GARD® assays are transforming skin sensitization testing. Learn about their role in filling data gaps for in vitro skin sensitizing hazard and quantitative potency assessment\, providing a high-performing and ethical alternative to animal testing. \nExhibitor-Hosted Session\nAdvancing NAMs for Skin Sensitization Testing: Potency\, Challenging Substances and Medical Devices \nW208B | Tuesday\, 18 Mar | 10:45 am-11:45 am \n \n  \nBring your questions and testing challenges!\n \nJoin us for an interactive session that combines essential regulatory updates\, case studies\, and a live Q&A! Gain exclusive insights on the latest GARD®data from SenzaGen’s research and industry collaborations\, including key advancements in testing challenging substances\, medical devices\, and quantitative potency assessment. We will also share user cases from industry leaders like dōTERRA\, Clarins\, and Bic Skin Creative. \nOur experts will be available to discuss how GARD® innovations can address your needs and advance your work in skin sensitization testing. \nKey Topics \n\nNew GARD® data from industry collaborations on Natural Extracts and Quantitative Potency Assessment.\nRegulatory update WG8 ISO TC194: Medical Devices ISO 10993-10.\nUser Cases from dōTERRA\, Clarins\, Bic Skin Creative\, and more.\n\nSpeakers \n\nRon Brown\, Toxicologist at Risk Science Consortium (former FDA reviewer for Medical Devices)\nJoe Dawson\, Product Safety Manager at doTERRA International\nAndy Forreryd\, Scientific Liaison\, SenzaGen\n\nPosters\n🎫 G367 | Skin Sensitization Potency GHS/CLP Classification \nMarch 17\, 1:45 pm -4:15 pm | #3242 Subcategorization of skin sensitizers into UN GHS categories using GARD®skin Dose-Response \n🎫 D217 | Medical Devices Testing ISO 10993-10 \nMarch 19\, 9:15 am -11:45 am | #4382 Pre-validation Results from GARD®skin for Medical Devices: In Vitro Sensitization Testing of Medical Device Extracts for Implementation in ISO 10993-10 \n🎫 LB352 | NAMs in Occupational Health – Joint poster with Lundbeck \nMarch 20\, 8:30 am -11:30 am | #5251 Assessing skin sensitizing hazard of Drug Products and Active Pharmaceutical Ingredients using GARD®: New Approach Methodology in Occupational Health and Safety \n🎫 F310 |  Application for Pharmaceuticals – Joint poster presented by SafeBridge \nMar 18\, 1:45 pm-4 pm | #3838 Comparison of β-lactam ring containing substances gene expression signatures related to therapeutic mechanism and the Adverse Outcome Pathway (AOP) for sensitization \n 
URL:https://senzagen.com/event/2025sot/
LOCATION:Orlando\, Fl\, United States
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/02/2025-SOT.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250306T160000
DTEND;TZID=Europe/Stockholm:20250306T170000
DTSTAMP:20260429T184405
CREATED:20250219T140200Z
LAST-MODIFIED:20250219T145527Z
UID:34108-1741276800-1741280400@senzagen.com
SUMMARY:Webinar: Regulatory updates & industry perspectives on NAMs for Medical Device Safety
DESCRIPTION:Join us for an insightful webinar on the evolving role of New Approach Methodologies (NAMs) in regulatory biological safety assessments and how they can be used to help develop safe materials in the pre-regulatory space. With shifting standards and increasing adoption of NAMs\, understanding their impact is more critical than ever. \nIn this webinar\, Dr Andy Forreryd\, our expert in in vitro skin sensitization and active member of ISO/TC 194/WG 8\, will break down the latest regulatory updates on ISO 10993-10 and present new data from the GARD®skin Medical Device pre-validation study—a key milestone toward regulatory acceptance. \nYou will also hear from Dr Karla Lienau\, Biological Safety Specialist and Research Engineer at Sonova\, a global leader in Medical Devices\, on how NAMs are shaping product development\, ensuring compliance\, and accelerating innovation. \n \nKey takeaways\n\nRegulatory insights: Understand the latest developments in ISO 10993-10 and the role of in vitro methods.\nGARD® advancements: Learn how this technology supports skin sensitization testing for Medical Devices\, solid materials and extracts in both polar and non-polar vehicles.\nIndustry application: Discover how Sonova integrates NAMs into product development for novel materials.\n\nSpeakers \n \nAndy Forreryd\, PhD\nScientific Liaison @ SenzaGen \n\nExpert in in vitro assay development\, genomics\, and machine learning.\nCo-developer of the GARD®skin assay (OECD TG 442E).\nActive member of the ISO/TC 194/WG 8 on irritation and sensitization and OECD expert group on respiratory sensitization.\n\n\n \nKarla Lienau\, PhD\nBiological Safety Specialist and Research Engineer @ Sonova \n\nResearch engineer specializing in new materials\, coatings\, and technologies for custom hearing aids.\nExpertise in biological safety assessments in compliance with ISO 10993.\nWorks with Class IIa Medical Devices\, ensuring safety and regulatory compliance.\n\n  \n \nThe webinar will last around 50 minutes\, followed by a live Q&A. If you cannot attend the live event\, register now to get access to the recording.
URL:https://senzagen.com/event/webinar-regulatory-updates-nams-for-medical-devices/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/01/Lime-UNIVERSAL-webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250213T160000
DTEND;TZID=Europe/Stockholm:20250213T170000
DTSTAMP:20260429T184405
CREATED:20250117T160857Z
LAST-MODIFIED:20250207T131544Z
UID:33984-1739462400-1739466000@senzagen.com
SUMMARY:Webinar: Overcoming the challenges of testing Natural Extracts with GARD technology
DESCRIPTION:Join SenzaGen and industry leaders from Clarins and Bic Skin Creative for an in-depth webinar on using GARD® assays for skin sensitization testing.  \nLearn how this innovative technology overcomes the unique challenges of testing complex Natural Extracts\, which often fall outside the scope of traditional methods in OECD 442E Test Guidelines. \nThrough case studies\, we will showcase how GARD® has supported the safety assessment of natural extract-based products\, providing reliable solutions for today’s testing needs. \n \nKey learnings and highlights\n\nChallenges of testing complex natural extracts with conventional methods.\nHow the GARD® technology brings new opportunities to the field of skin sensitization.\nCase studies from Clarins and Bic Skin Creative on applying GARD® for natural extract safety assessments.\n\nAgenda and speakers\n1. Advancing skin sensitization testing with GARD®: Spotlight on Natural Extracts\n \nAndy Forreryd\, PhD\nScientific Liaison @ SenzaGen \nDr Forreryd has many years of experience working with in vitro assay development\, genomics and machine learning\, engaging in collaborations with industry leaders to investigate novel applications for NAM-based sensitization testing\, with the aim to replace the need for animal studies. He is co-developer of the GARDskin assay (OECD TG 442) for the assessment of chemical sensitizers. \n2. Safety assessment of raw materials extracted from plants using GARD®\n \nMylène Landais\nSafety Assessor @ Clarins \nMylène Landais is a toxicology expert currently working for the Clarins Group as an ingredient and formulas safety assessment project manager. She holds a master’s degree in toxicology and\, with 10 years of experience in the cosmetic industry\, mainly works on the safety assessment and risk assessment of finished products and ingredients such as plant extracts and synthetic ingredients. \nThis role is key to ensure the safety of cosmetic products consumers by using alternative to animal testing methods while complying with the main regulations worldwide and facing new challenges\, such as the new Chinese cosmetic regulation. \n3. Assessing skin sensitization potential of new skin-binding dyes using the GARD®skin Dose-Response assay\n \nIan Mallov\nManager of Scientific Research @ Bic Skin Creative \nIan Mallov is manager of scientific research at Bic Skin Creative. Ian grew up in Truro\, Nova Scotia\, Canada and holds a Ph.D. in inorganic chemistry from the University of Toronto. He began as an industrial postdoctoral researcher in the lab of Prof. Chris Caputo at York University with Toronto-based start-up Inkbox Ink. As Inkbox was acquired by Bic\, his role shifted to focus on assessing the efficacy and toxicology of derivatives of natural skin-binding dyes. In his spare time\, he enjoys writing\, running\, and ice hockey. Ian lives in Halifax\, Nova Scotia with his wife and six-month-old daughter. \nWhat are Natural Extracts?\nNatural extracts are are ingredients derived from natural sources like plants and herbs. They are often classified as UVCBs (Unknown or Variable composition\, Complex reaction products\, or Biological materials). These complex substances present unique testing challenges and frequently fall outside the applicability domains of conventional in vitro assays included in OECD Test Guideline for skin sensitization assessment. \n  \n \nThe webinar will last around 50 minutes\, followed by a live Q&A. If you cannot attend the live event\, register now to get access to the recording.
URL:https://senzagen.com/event/webinar-natural-extracts/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/01/Lime-UNIVERSAL-webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20241120T160000
DTEND;TZID=Europe/Stockholm:20241120T170000
DTSTAMP:20260429T184405
CREATED:20241105T080455Z
LAST-MODIFIED:20241105T094128Z
UID:33676-1732118400-1732122000@senzagen.com
SUMMARY:Webinar: In vitro skin sensitization testing: Ensuring conclusive results for challenging samples
DESCRIPTION:Join us for a special re-run of our popular GARD® webinar to explore the recent advancement in Skin Sensitization testing\, focusing on substances that fall outside the applicability domains of the conventional in vitro assays in the OECD Test Guidelines. \nOur skin sensitization experts will address challenges posed by various “Difficult-to-Test” substances\, discussing the applicability domain of key event-based NAMs and existing test strategies. \nYou will learn about the broad applicability of GARD®skin (OECD TG442E) as we review scientific data on challenging substances and exciting projects done in collaboration with industry partners: \nAgrochemical Formulations | Formulated Lubricant Products | Indirectly Acting Haptens | Metals | Natural Extracts | Polymers | UVCBs \nRecorded webinar with live Q&A\nThis recorded webinar will last approximately 45 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording.  \nKey takeaways\n\nNAMs and test strategies for skin sensitization testing of challenging samples.\nThe applicability domain of GARD®skin for challenging substances and its integration into Defined Approaches.\nCase studies on Agrochemical Formulations\, Formulated Lubricant Products\, Indirectly Acting Haptens\, Metals\, Natural Extracts\, Polymers\, and UVCBs.\n\nWhat are challenging /“difficult-to-test” substances?\nIn the context of skin sensitization testing\, certain groups of chemicals are considered difficult to test using conventional cell-based methods. Examples of commonly recognised “difficult-to-test” samples include indirectly acting haptens\, complex mixtures\, and substances with low water solubility. \nRead more about difficult-to-test substances. \nSpeaker\n \n  \n \n 
URL:https://senzagen.com/event/webinar-spotlight-on-challenging-samples/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2024/11/BANNER-2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241028
DTEND;VALUE=DATE:20241031
DTSTAMP:20260429T184405
CREATED:20240905T122507Z
LAST-MODIFIED:20250317T085918Z
UID:33088-1730073600-1730332799@senzagen.com
SUMMARY:ASCCT 13th Annual Meeting
DESCRIPTION:Meet us at the American Society for Cellular and Computational Toxicology (ASCCT) Annual Meeting in Research Triangle Park\, North Carolina. \n  \nOral presentation | Monday\, 28 October | 17:20-17:35\nNAMs for botanical safety evaluation: Case Study on Determine the Safe Use Levels of Genipa Plant Extract in Temporary Tattoo Ink with GARD®\n  \nPoster\nGARD®skin Dose-Response for skin sensitizing potency assessment: Performance on the Reference Chemical Potency List (RCPL)
URL:https://senzagen.com/event/ascct-13th-annual-meeting/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2024/09/24050-RAD-ASCCT-13th-Annual-Meeting-Graphics-1584x39676_Page_1-scaled-e1725539063290.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20241009T160000
DTEND;TZID=Europe/Stockholm:20241009T170000
DTSTAMP:20260429T184405
CREATED:20240905T141518Z
LAST-MODIFIED:20240924T125128Z
UID:33109-1728489600-1728493200@senzagen.com
SUMMARY:Webinar: Advancing NAMs for Skin Sensitization Testing
DESCRIPTION:Spotlight on Point-of-Departure\, Challenging Substances\, and Active Ingredients\nWe invite you to join our upcoming webinar\, where industry leaders from Lundbeck\, Unilever\, and Cargill\, along with experts from SenzaGen will explain the latest advancements in skin sensitization testing. \nJoin us as we explore the latest data from our GARD® platform on skin sensitization and gain insights from leading industry experts. We will also highlight case studies from collaborative projects\, including those with L’Oréal and ExxonMobil Biomedical Sciences. \nIf you missed SenzaGen’s scientific presentations at Eurotox this year\, this webinar is your chance to catch up on the most recent developments. \nThe webinar will last around 50 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording. \n \nKey topics\n\nDifficult-to-Test Samples\nUVCBs and Formulated Lubricant Products\nHydrophobic Esters\nDrug products and Active Substances\nPoint-of-Departure for Quantitative Risk Assessment\nDefined Approaches\nIndustry collaborations: Case studies and publications\n\nDon’t miss out on this opportunity to gain valuable insights and network with experts in the field! \nSpeakers\n \n \n \n \n \n 
URL:https://senzagen.com/event/webinar2024eurotoxhighlights/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2024/09/FINAL-Eurotox-sep-2024-1200x1200px-1-e1727179193578.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240908T080000
DTEND;TZID=Europe/Stockholm:20240911T170000
DTSTAMP:20260429T184405
CREATED:20240126T092505Z
LAST-MODIFIED:20240905T105818Z
UID:31912-1725782400-1726074000@senzagen.com
SUMMARY:Eurotox 2024
DESCRIPTION:Meet us at Booth #56\nCome meet us at booth #56 and join our presentations to hear the latest news about GARD® and how the assays are used to fill data gaps in skin sensitizing hazard and quantitative potency assessment. Additionally\, meet ToxHub\, a SenzaGen Group company\, and benefit from expert toxicology and regulatory advice. \n  \n \nIndustry-Hosted Session\n“Advancing NAMs for Skin Sensitization” \nGuest speakers from Lundbeck and Unilever\n \nPosters\nSpotlight on Hydrophobic Esters\, PoD\, Defined Approaches\, and more\n🎫 P01-79 #996 | Joint poster with Cargill\nThe applicability of GARD®skin for assessing skin sensitization potential of hydrophobic esters during product development \n🎫 P19-57 #661 | Joint poster with L’Oréal\nImproved Confidence of Quantitative Sensitizing Potency Assessment for Point of Departure Using GARD®skin Dose-Response \n🎫 P19-75 #840 | Joint poster with Sonova\nIntegrating NAMs into early-stage screening of novel materials intended for use in Medical Devices: Case studies on the use of GARD® for in vitro skin sensitization assessment \n🎫 P20-17 #613 | SenzaGen poster\nGARD®skin as a drop-in replacement KE3-method in OECD GD 497 Defined Approaches \n🎫 P23-21 #937 | ToxHub poster\nWorkflow for Occupational Exposure Limit Determination and Banding: Focus on Skin and Respiratory Sensitization using NAMs approaches \n🎫 LP-28 | ToxHub poster\nRisk Assessment Approaches for Nanomaterials in Medical Devices \n 
URL:https://senzagen.com/event/eurotox2024/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2024/01/Lime-banner-new-v2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240627T160000
DTEND;TZID=Europe/Stockholm:20240627T170000
DTSTAMP:20260429T184405
CREATED:20240521T140048Z
LAST-MODIFIED:20240613T062934Z
UID:32293-1719504000-1719507600@senzagen.com
SUMMARY:Webinar: Meta-analysis of GARD® data\, 200+ chemicals
DESCRIPTION:Spotlight on in vitro quantitative assessment of skin sensitizing potency.\nJoin our upcoming webinar to explore the recent advancement in GARD® for quantitative assessment of skin sensitizing potency.  \nThis session will present a meta-analysis of GARD® data covering over 200 chemicals\, including three blinded datasets generated in collaboration with industry partners. \nThese data will demonstrate how GARD® can estimate a Point of Departure (PoD) and be incorporated into downstream strategies for Quantitative Risk Assessment (QRA)\, contributing to the assessment of safe use levels of chemicals. \nYou will learn how the assay can be used to predict LLNA EC3 values\, Human NOELs\, and GHS/CLP classifications (1A or 1B). \nThe webinar will last around 30 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording. \n \nKey topics\n\nAn introduction to the prediction model\, genomics\, and machine learning technology.\nThe GARD® assay’s performance in predicting PoD for QRA.\nHow the GARD® assay ensures the safe use of ingredients in consumer products.\n\nSpeakers\n \n 
URL:https://senzagen.com/event/webinar-meta-analysis-of-gard-data/
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240612T080000
DTEND;TZID=Europe/Stockholm:20240614T170000
DTSTAMP:20260429T184405
CREATED:20240126T094148Z
LAST-MODIFIED:20240126T094148Z
UID:31924-1718179200-1718384400@senzagen.com
SUMMARY:ITCASS and ERGECD meeting 2024
DESCRIPTION:Meet us in Liverpool at the the 11th meeting of Immunotoxicology & Chemical Allergy (ITCASS) and the 30th meeting of European Research Group on Experimental Contact Dermatitis (ERGECD).
URL:https://senzagen.com/event/itcass-and-ergecd-meeting-2024/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240603T080000
DTEND;TZID=Europe/Stockholm:20240606T170000
DTSTAMP:20260429T184405
CREATED:20240126T091543Z
LAST-MODIFIED:20240521T140249Z
UID:31906-1717401600-1717693200@senzagen.com
SUMMARY:ESTIV Congress 2024
DESCRIPTION:Come meet us at booth #22 and join our presentations to hear the latest news about GARD® and how the assays are used to fill data gaps for skin sensitizing hazard and quantitative potency assessment.  \nAdditionally\, meet ToxHub\, a SenzaGen Group company\, and benefit from expert toxicology and regulatory advice. \nPresentations and Posters\nOur team will showcase several posters and presentations. Dive into new scientific data and discover exciting projects done in collaboration with industry partners. \nTuesday 09:00-10:30 | Presentation in Session 2b\nProject in collaboration with L’Oreal. “Improved confidence of quantitative sensitizing potency assessment for PoD using GARD®skin Dose-Response”\n\nThursday 11:30-12:45 | Presentation in Session 9a\n“Regulatory approval of medical devices according to MDR using in vitro data from GARD®skin Medical Device for skin sensitization assessment” \nPoster | Presented by ToxHub\n#334 | “Integrated Risk Assessment and Compliance Strategies for Nanomaterials in Medical Devices”
URL:https://senzagen.com/event/estiv-congress-2024/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2024/01/ESTIV-banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240529T090000
DTEND;TZID=Europe/Stockholm:20240530T170000
DTSTAMP:20260429T184405
CREATED:20240521T135437Z
LAST-MODIFIED:20240527T133353Z
UID:32280-1716973200-1717088400@senzagen.com
SUMMARY:Cosmetotest
DESCRIPTION:Program\n‘Introduction to GARDskin (OECD TG 442E) for evaluation of skin sensitization hazard with dose-response option for quantitative risk assessment’\nDate: 30/05\nSession 1: Safety: from irritation to sensitization\nPresenter: Andy Forreryd\, SenzaGen \nBooth: #21
URL:https://senzagen.com/event/cosmetotest/
LOCATION:ENS Lyon\, France
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2024/05/LinkedIn-banner-v1-e1716816802689.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240423T160000
DTEND;TZID=Europe/Stockholm:20240423T170000
DTSTAMP:20260429T184405
CREATED:20240321T085330Z
LAST-MODIFIED:20240325T130110Z
UID:32117-1713888000-1713891600@senzagen.com
SUMMARY:Webinar: Advancing NAMs for Skin Sensitization Testing
DESCRIPTION:Spotlight on Applicability Domain\, Quantitative Potency Assessment and Medical Devices\nIn case you missed SenzaGen’s poster presentations and scientific session at this year’s SOT\, we are pleased to offer you a new opportunity to participate on April 23\, 2024! \nIn this webinar Dr Andy Forreryd\, SenzaGen’s in vitro toxicology expert\, will summarize the latest GARD data from industry collaborations: \nCorteva Agriscience | ExxonMobil Biomedical Sciences | L’Oréal | IFF | RIFM | Inotiv | Johnson Matthey | Sonova | Duearity \nThe webinar will last around 50 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording.  \nKey topics\n\nAgrochemical Formulations\nUVCBs and Formulated Lubricant Products\nComplex Mixtures\nMetals\nPoD for Quantitative Risk Assessment\nNESILs for Fragrance Materials\nRegulatory Acceptance According to MDR\nEarly-stage screening of materials intended for use in Medical Devices\n\nSpeakers\n \n  \n \n 
URL:https://senzagen.com/event/webinar-advancing-nams-for-skin-sensitization-testing/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2024/03/Lime_webinar-final.jpg
END:VEVENT
END:VCALENDAR